8-K - Tectonic Therapeutic, Inc. (0001681087) (Filer)

10-Q - Tectonic Therapeutic, Inc. (0001681087) (Filer)

EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

424B3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

EFFECT - Tectonic Therapeutic, Inc. (0001681087) (Filer)

POS AM - Tectonic Therapeutic, Inc. (0001681087) (Filer)

POS AM - Tectonic Therapeutic, Inc. (0001681087) (Filer)

S-3 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

424B5 - Tectonic Therapeutic, Inc. (0001681087) (Filer)

Truist initiated coverage of Tectonic Therapeutic with a rating of Buy and set a new price target of $64.00

Raymond James resumed coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $76.00

Mizuho initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $51.00

Raymond James initiated coverage of Tectonic Therapeutic with a rating of Outperform and set a new price target of $65.00

Wells Fargo initiated coverage of Tectonic Therapeutic with a rating of Overweight and set a new price target of $55.00

Piper Sandler initiated coverage of Tectonic Therapeutic with a rating of Overweight

TD Cowen initiated coverage of Tectonic Therapeutic with a rating of Buy

WATERTOWN, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in three upcoming investor conferences taking place in September 2025. 2025 Wells Fargo Healthcare Conference Date:September 3, 2025Location:Boston, MAFormat:Investor Meetings   Cantor Global Healthcare Conference Date:September 4, 2025Time:2:10 PM EDTLocation:New York, NYFormat:Fireside ChatPresenters:Daniel Lochner, Chief F

TX45 PH-ILD Phase 2 clinical trial is planned to initiate in 2026 to evaluate TX45's safety and hemodynamic effects in subjects with Pulmonary Hypertension associated with Interstitial Lung Disease ("PH-ILD", Group 3 PH) to expand the therapeutic breadth of TX45 Complete results from Part A of the TX45 Phase 1b clinical trial presented at ESC Heart Failure 2025 confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in subjects with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")Part B of the TX45 Phase 1b clinical trial in subjects with Group 2 Pulmonary Hypertension in Heart Failure with r

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000® Index. Tectonic's addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization.

Data confirmed TX45's tolerability profile and improvements in left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF")In new echocardiographic analysis, TX45 treatment resulted in sustained hemodynamic effects for 29 daysTX45 improved cardiac and pulmonary hemodynamics in PH-HFpEF patients across a range of left ventricular ejection fractions ("LVEF"), including LVEF≥50% and LVEF 41-49% WATERTOWN, Mass., May 17, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic") today announced the complete results from Part A of the Phase 1b clinical trial of TX45 in pat

Interim analysis from the TX45 Phase 1b Part A trial demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Full results from the Phase 1b Part A trial will be presented on May 17, 2025 at the European Society of Cardiology (ESC) Heart Failure Congress in Belgrade, SerbiaPart B of the TX45 Phase 1b trial initiated in March with topline results expected in the second half of 2025Ongoing TX45 APEX Phase 2 trial continues to enroll with topline results expected in 2026Cash and cash equivalents were $306.2 million as of March 31, 2025, including

WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date:Thursday, May 15th, 2025Time:9:20am PDTFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link The

WATERTOWN, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced that it will make a late-breaking oral presentation at the European Society of Cardiology (ESC) Heart Failure 2025 Congress. The presentation will highlight Phase 1b data for TX45, Tectonic's lead asset and a long-acting relaxin therapy as a potential best-in-class therapy for patients with Group 2 PH-HFpEF. The presentation at ESC Heart Failure 2025 will include the full Phase 1b PH

TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction ("PH-HFpEF")Positive TX45 Phase 1b interim results support endpoints and patient population in ongoing APEX Phase 2 trial, with topline results expected in 2026TX45 Phase 1b Part B trial enrolled its first subject with Heart Failure with reduced Ejection Fraction ("HFrEF") in March 2025Cash and cash equivalents of $141.2 million as of December 31, 2024 and February 2025 private placement gross proceeds of approximately $185.0 million, together expected to provide

WATERTOWN, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that company management will participate in two upcoming investor conferences taking place in March 2025. TD Cowen 45th Annual Health Care Conference Date:March 5, 2025Time:9:50 AM ESTLocation:Boston, MAFormat:Corporate PresentationPresenter:Alise Reicin, MD, President and Chief Executive OfficerWebcast:Link  Leerink Partners Global Healthcare ConferenceDate: March 11, 2025Time:11:20 A

WATERTOWN, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic"), today announced that it has entered into a securities purchase agreement for a private investment in public equity financing (the "PIPE") that is expected to result in gross proceeds of approximately $185.0 million. Pursuant to the terms of the securities purchase agreement, at the closing of the PIPE, Tectonic will issue an aggregate of 3,689,465 shares of common stock at a price of $50.00 per share to fund investors and $54.14 per share to individual investors that are either an officer or director of Tectonic. The PIPE financing included participation from new and existing invest

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

4 - Tectonic Therapeutic, Inc. (0001681087) (Issuer)

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ("PH-HFpEF"), supporting endpoints and patient population in ongoing APEX Phase 2 clinical trialInterim analysis demonstrated that TX45 achieved 17.9% reduction in Pulmonary Capillary Wedge Pressure ("PCWP") in the total study population of PH-HFpEF and >30% reduction in Pulmonary Vascular Resistance ("PVR") in Combined pre- and post-capillary PH ("CpcPH"), a subpopulation with more severe diseaseTX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events, significant hypotension, or immune rel

Patient enrollment in the Phase 1b hemodynamic trial remains ahead of expectation, with topline results now expected in late Q1'2025 or early Q2'2025First subject dosed with TX000045 ("TX45") in APEX Phase 2 clinical trial in early October, with topline results expected in 2026Development Candidate TX002100 ("TX2100") selected for second program targeting patients with Hereditary Hemorrhagic Telangiectasia (HHT)Cash and cash equivalents were $159.1 million as of September 30, 2024, expected to provide cash runway into mid-2027 WATERTOWN, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotechnology compan

TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in July 2024Completed reverse merger with AVROBIO in June 2024, including concurrent private placement of $130.7 millionCash and cash equivalents were $185.1 million as of June 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ:TECX) ("Tectonic", or "the Company"), a clinical-stage biotech

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G/A - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13G - Tectonic Therapeutic, Inc. (0001681087) (Subject)

SC 13D - Tectonic Therapeutic, Inc. (0001681087) (Subject)